sites were pooled according to geographiclocation to prevent the loss of too manydegrees of freedom in the model. Thispooling took into account the number ofendocrinologists, patient accessibility tospecialty diabetes care, and managed carein the geographic locations. The intent-to-treat (ITT) population was deﬁned as all randomized subjectswho received at least one injection of ran-domized medication starting from theevening of day 1. All efﬁcacy and safetyanalyses were performed on the ITT pop-ulation, with the exception of the percent-age of subjects achieving HbA 1c/H113497% by week 30. For the latter analysis, the more